BRAF and metastatic melanoma: In December of 2014, the FDA granted approval for Nivolumab, commercially known as Opdivo, for the treatment of metastatic melanoma in patients who had previously been treated with Ipilimumab and also for those who had become BRAF V600 mutation positive after treatment with a BRAF inhibitor.